Effects of montelukast sodium tablets combined with pulmicort aerosol in the treatment of children with asthma and its influence on EOS, IL-4, IgE, TNF-α

Qi Sun, Haijun Yang
{"title":"Effects of montelukast sodium tablets combined with pulmicort aerosol in the treatment of children with asthma and its influence on EOS, IL-4, IgE, TNF-α","authors":"Qi Sun, Haijun Yang","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.06.016","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the effect of montelukast sodium tablets combined with pulmicort aerosol in the treatment of children with asthma, and its influence on eosinophil (EOS), interleukin-4 (IL-4), immunoglobulin E (IgE), tumor necrosis factor-α (TNF-α). \n \n \nMethods \nFrom March 2018 to March 2019, 142 children with asthma admitted to Hangzhou Dajiangdong Hospita were randomly divided into observation group (71 cases) and control group (71 cases) according to the digital table.The patients in the observation group were treated with montelukast sodium tablets combined with pulmicort aerosol, while patients in the control group were treated with pulmicort aerosol.Both two groups were treated for 2 weeks.The levels of EOS, IL-4, IgE and TNF-α, day and night asthma symptom scores and blood gas analysis indicators before and after treatment were compared between the two groups. \n \n \nResults \nThe total effective rate of the observation group (91.55%) was higher than that of the control group (74.65%) (χ2=7.220, P<0.05). After treatment, the scores of asthma symptoms in day[(0.38±0.12)points] and night[(0.42±0.14)points] in the observation group were lower than those in the control group[(0.87±0.19)points and (0.93±0.25)ponts](t=18.373, 14.998, all P<0.05). After treatment, the levels of EOS[(0.38±0.09)×109/L], IL-4[(13.89±3.25)ng/L], IgE[(109.35±16.57)kU/L] and TNF-α[(1.25±0.12)ng/L] in the observation group were lower than those in the control group[(0.73±0.13)×109/L, (18.36±2.70)ng/L, (164.53±23.51)kU/L and (1.49±0.15)ng/L](t=18.652, 8.914, 16.165, 10.528, all P<0.05). \n \n \nConclusion \nMontelukast sodium tablets combined with pulmicort aerosol is effective in the treatment of children with asthma.It can reduce the levels of EOS, IL-4, IgE and TNF-α, alleviate the symptoms of daytime and night asthma. \n \n \nKey words: \nAsthma; Eosinophils; Interleukin-4; Immunoglobulin E; Tumor necrosis factor-a; Montelukast sodium; Pulmicort aerosol; child","PeriodicalId":10226,"journal":{"name":"中国基层医药","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国基层医药","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.06.016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective To investigate the effect of montelukast sodium tablets combined with pulmicort aerosol in the treatment of children with asthma, and its influence on eosinophil (EOS), interleukin-4 (IL-4), immunoglobulin E (IgE), tumor necrosis factor-α (TNF-α). Methods From March 2018 to March 2019, 142 children with asthma admitted to Hangzhou Dajiangdong Hospita were randomly divided into observation group (71 cases) and control group (71 cases) according to the digital table.The patients in the observation group were treated with montelukast sodium tablets combined with pulmicort aerosol, while patients in the control group were treated with pulmicort aerosol.Both two groups were treated for 2 weeks.The levels of EOS, IL-4, IgE and TNF-α, day and night asthma symptom scores and blood gas analysis indicators before and after treatment were compared between the two groups. Results The total effective rate of the observation group (91.55%) was higher than that of the control group (74.65%) (χ2=7.220, P<0.05). After treatment, the scores of asthma symptoms in day[(0.38±0.12)points] and night[(0.42±0.14)points] in the observation group were lower than those in the control group[(0.87±0.19)points and (0.93±0.25)ponts](t=18.373, 14.998, all P<0.05). After treatment, the levels of EOS[(0.38±0.09)×109/L], IL-4[(13.89±3.25)ng/L], IgE[(109.35±16.57)kU/L] and TNF-α[(1.25±0.12)ng/L] in the observation group were lower than those in the control group[(0.73±0.13)×109/L, (18.36±2.70)ng/L, (164.53±23.51)kU/L and (1.49±0.15)ng/L](t=18.652, 8.914, 16.165, 10.528, all P<0.05). Conclusion Montelukast sodium tablets combined with pulmicort aerosol is effective in the treatment of children with asthma.It can reduce the levels of EOS, IL-4, IgE and TNF-α, alleviate the symptoms of daytime and night asthma. Key words: Asthma; Eosinophils; Interleukin-4; Immunoglobulin E; Tumor necrosis factor-a; Montelukast sodium; Pulmicort aerosol; child
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
孟鲁司特钠片联合普米克气雾剂治疗儿童哮喘及其对EOS、IL-4、IgE、TNF-α的影响
目的探讨孟鲁司特钠片联合普米克气雾剂治疗儿童哮喘的疗效及其对嗜酸性粒细胞(EOS)、白细胞介素-4(IL-4)、免疫球蛋白E(IgE)、肿瘤坏死因子-α(TNF-α)的影响。方法自2018年3月至2019年3月,将杭州大江东医院收治的142例哮喘患儿按数字表随机分为观察组71例和对照组71例。观察组采用孟鲁司特钠片联合普米克气雾剂治疗,对照组采用普米克气溶胶治疗。两组均治疗2周。比较两组治疗前后EOS、IL-4、IgE、TNF-α水平、昼夜哮喘症状积分及血气分析指标。结果观察组总有效率(91.55%)高于对照组(74.65%)(χ2=7.220,P<0.05)。治疗后,观察组哮喘症状白天[(0.38±0.12)分]和夜间[(0.42±0.14)分]评分均低于对照组[(0.87±0.19)分和(0.93±0.25)分](t=18.373,14.998,均P<0.05),109/L]、IL-4[(13.89±3.25)ng/L]、,观察组IgE[(109.35±16.57)kU/L]和TNF-α[(1.25±0.12)ng/L]均低于对照组[(0.73±0.13)×109/L、(18.36±2.70)ng/L、(164.53±23.51)kU/L和(1.49±0.15)ng/L](t=18.652、8.914、16.165、10.528,均P<0.05)。可降低EOS、IL-4、IgE和TNF-α水平,缓解昼夜哮喘症状。关键词:哮喘;嗜酸性粒细胞;白细胞介素-4;免疫球蛋白E;肿瘤坏死因子-a;孟鲁司特钠;普米克气雾剂;儿童
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.10
自引率
0.00%
发文量
32251
期刊介绍: Since its inception, the journal "Chinese Primary Medicine" has adhered to the development strategy of "based in China, serving the grassroots, and facing the world" as its publishing concept, reporting a large amount of the latest medical information at home and abroad, prospering the academic field of primary medicine, and is praised by readers as a medical encyclopedia that updates knowledge. It is a core journal in China's medical and health field, and its influence index (CI) ranks Q2 in China's academic journals in 2022. It was included in the American Chemical Abstracts in 2008, the World Health Organization Western Pacific Regional Medical Index (WPRIM) in 2009, and the Japan Science and Technology Agency Database (JST) and Scopus Database in 2018, and was included in the Wanfang Data-China Digital Journal Group and the China Academic Journal Comprehensive Evaluation Database.
期刊最新文献
桑寄生提取物对肾性高血压大鼠降压作用的初步研究 Analysis of related factors in deep venous thrombosis of lower extremity when using limb blood circulation pump in patients with spinal cord injury Research progress on mycoplasma pneumoniae infection and high-density lipoprotein metabolism Diagnostic value of serum microRNA21 and tumor markers CEA, CYFRA21-1 and NSE in early non-small cell lung cancer Effect of methylene diphosphate combined with strontium chloride in the treatment of bone pain caused by multiple bone metastases
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1